We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
126
IDEAYA Biosciences
IDYA
$3.43B
– –
-1,141,484
Closed -$4.7M
LITS
127
Lite Strategy Inc
LITS
$32.4M
– –
-151,522
Closed -$4.88M
MREO
128
Mereo BioPharma
MREO
$49.8M
– –
-179,419
Closed -$187K
RGNX icon
129
Regenxbio
RGNX
$611M
– –
-508,000
Closed -$17.1M
RYTM icon
130
Rhythm Pharmaceuticals
RYTM
$7.34B
– –
-170,859
Closed -$2.6M
SDGR icon
131
Schrodinger
SDGR
$1.12B
– –
-250,000
Closed -$10.5M
SPY icon
132
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$776B
– –
-325,000
Closed -$159K
TARA icon
133
Protara Therapeutics
TARA
$213M
– –
-8,543
Closed -$184K
TBPH icon
134
Theravance Biopharma
TBPH
$875M
– –
-1,000,000
Closed -$23.1M
TXG icon
135
10x Genomics
TXG
$5.86B
– –
-220,000
Closed -$13.8M
TXMD icon
136
TherapeuticsMD
TXMD
$23.7M
– –
-21,922
Closed -$1.17M
ZBH icon
137
Zimmer Biomet
ZBH
$18.6B
– –
-51,500
Closed -$4.91M
AXNX
138
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-50,000
Closed -$1.19M
MRTX
139
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$149K
CERN
140
DELISTED
Cerner Corp
CERN
– –
-105,000
Closed -$6.75M
XLRN
141
DELISTED
Acceleron Pharma
XLRN
– –
-6,813
Closed -$583K
IMVTU
142
DELISTED
Immunovant, Inc. Units
IMVTU
– –
-400,000
Closed -$7.36M
ZGNX
143
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-300,000
Closed -$724K
2 3 4 5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.